Clinical trial
Adenovirus Vaccine for Malaria
NCT00371189 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00371189 |
|---|---|
| Title | Adenovirus Vaccine for Malaria |
| Official title | A Phase I Randomized, Controlled, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Healthy Adults 18 to 45 Years of Age |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Plasmodium Falciparum Infection |
| Intervention type | Biological, Drug |
| Interventions | Placebo, Ad35.CS.01 Circumsporozoite Malaria Vaccine |
| Enrollment | 75 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2014 |
| Completion | Jun 1, 2014 |
| First posted | Sep 1, 2006 |
| Last update posted | Sep 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: